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Background: A markedly high failure rate of three-day artesunate-mefloquine was observed in the area along the
Thai-Myanmar border.
Methods: Identification of Plasmodium falciparum isolates with intrinsic resistance to each component of the
artesunate-mefloquine combination was analysed with integrated information on clinico-parasitological response,
together with systemic drug exposure (area under blood/plasma concentration-time curves (AUC)) of
dihydroartemisinin and mefloquine, and in vitro sensitivity of P. falciparum in a total of 17 out of 29 P. falciparum
isolates from patients with acute uncomplicated falciparum malaria. Analysis of the contribution of in vitro parasite
sensitivity and systemic drug exposure and relationship with pfmdr1 copy number in the group with sensitive
response was performed in 21 of 69 cases.
Results: Identification of resistance and/or reduced intrinsic parasitocidal activity of artesunate and/or mefloquine
without pharmacokinetic or other host-related factors were confirmed in six cases: one with reduced sensitivity to
artesunate alone, two with resistance to mefloquine alone, and three with reduced sensitivity to artesunate
combined with resistance to mefloquine. Resistance and/or reduced intrinsic parasitocidal activity of mefloquine/
artesunate, together with contribution of pharmacokinetic factor of mefloquine and/or artesunate were identified in
seven cases: two with resistance to mefloquine alone, and five with resistance to mefloquine combined with
reduced sensitivity to artesunate. Pharmacokinetic factor alone contributed to recrudescence in three cases, all of
which had inadequate whole blood mefloquine levels (AUC0-7days). Other host-related factors contributed to
recrudescence in one case. Amplification of pfmdr1 (increasing of pfmdr1 copy number) is a related molecular
marker of artesunate-mefloquine resistance and seems to be a suitable molecular marker to predict occurrence of
recrudescence.
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Conclusions: Despite the evidence of a low level of a decline in sensitivity of P. falciparum isolates to artemisinins
in areas along the Thai-Myanmar border, artemisinin-based combination therapy (ACT) would be expected to
remain the key anti-malarial drug for treatment of multidrug resistance P. falciparum. Continued monitoring and
active surveillance of clinical efficacy of ACT, including identification of true artemisinin resistant parasites, is
required for appropriate implementation of malaria control policy in this area.
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The emergence and spread of multidrug resistant
Plasmodium falciparum is the key factor contributing
to complexity in malaria control. To deal with the threat
of resistance, artemisinin-based combination therapy
(ACT) is being promoted as a strategy to conteract the
increasing resistance of the parasite as well as to pre-
vent disease transmission [1]. Despite the precautionary
measures however, artemisinin-resistant P. falciparum
malaria has emerged in western Cambodia and the bor-
dering regions with Thailand, the hotspot of multidrug
resistance parasites [2-10], and appears to be emerging
in the western border of Thailand [11,12].
In Thailand, a three-day, artesunate-mefloquine com-
bination regimen has been used as the first-line treatment
for acute uncomplicated falciparum malaria throughout
the country [13]. In a previous study which aimed at
monitoring clinical efficacy of this three-day artesunate-
mefloquine combination regimen during the year 2009 in
134 patients with acute uncomplicated falciparum malaria
in the area along the Thai-Myanmar border, a markedly
high failure rate was observed [11]. The 28- and 42-day
cure rates calculated by Kaplan-Meier survival analysis
with PCR correction for re-infection were 74.7 and 68.1%,
respectively. It is noted that re-appearance of parasitaemia
occurred as early as seven days after the first dose. In
addition, there was a small but significant delay of parasite
clearance in the group with recrudescence response
(median (range) parasite clearance time 32.0 (28.0-34.0) h)
compared with the sensitive group (26.0 (24.0-26.0) h).
Only six (17.6%) and seven (20.5%) patients with recrudes-
cence response, respectively, had parasitaemia and fever
cleared within 24 hours. This observation is alarming and
is of great concern if resistance of P. falciparum has actu-
ally developed and spread in this area. In the present
study, identification of resistance/reduced sensitivity of
P. falciparum in this border area to each component of
this three-day, artesunate-mefloquine combination regi-
men was proposed based on clinico-parasitological re-
sponse, with confirmed adequacy of anti-malarial systemic
drug exposure during acute phase infection, and in vitro
sensitivity of P. falciparum isolates to each combination
partner. In addition, the possible link between the identi-
fied “resistance” cases and P. falciparum multidrugresistance 1 (pfmdr1) copy number, the candidate molecu-
lar markers of mefloquine and/or artesunate resistance
was investigated.Methods
Patients and study framework
The study was conducted at Mae Tao clinic for migrant
workers, Tak Province, Thailand [11]. Figure 1 summarizes
the total number of cases included in the study and num-
ber of cases included in each step of analysis. Prior to
study, approval of the study protocol was obtained from
the Ethics Committee of the Ministry of Public Health of
Thailand. Written informed consents were obtained from
all patients before study participation. The analysis for
identification of resistance of P. falciparum to artesunate-
mefloquine combination was performed in a total of 91
(62 cases with sensitive response and 29 with PCR-
confirmed recrudescence) Burmese patients (47 males and
44 females, aged between 16 and 57 years) with acute
uncomplicated P. falciparum malaria (median (95% CI)
admission parasitaemia 5,512 (5,040-6,930)/μl] [14]). Re-
appearance of parasitaemia in the 29 late parasitological
failure (LPF) cases occurred between day 7 and 42, with
significant prolongation of parasite and fever clearance
time (PCT nd FCT) in patients with recrudescence com-
pared with sensitive response (median (95% CI) 32.0
(28.0-34.0) vs 26.0 (24.0-26.0) h, and 32.0 (30.0-34.0) vs
26.0 (24.0-26.0) h, respectively). The study procedures and
results of clinical efficacy assessment, including relation-
ship with drug concentrations, were previously described
in detail [11]. In brief, patients were treated with the
standard three-day combination regimen of artesunate
and mefloquine with primaquine (4 mg/kg body weight
artesunate daily for three days; 750 and 500 mg meflo-
quine on the first and second day, respectively; 0.6 mg/kg
body weight primaquine on the third day). All were admit-
ted to the clinic during the course of treatment or until
signs and symptoms of malaria disappeared. Prior to treat-
ment, blood sample (5 ml) was collected from each patient
for in vitro sensitivity testing of P. falciparum isolates to
artesunate and mefloquine, genetic analysis (molecular
markers of recrudescence and drug resistance) and deter-
mination of baseline anti-malarial drug concentrations
Figure 1 Summary of cases included in the analysis of each step (clinico-parasitological response, pfmdr1 copy number, in vitro
parasite sensitivity to artemisinin and mefloquine and drug levels (dihydroartemisinin and mefloquine). a = Reference [11].
Na-Bangchang et al. Malaria Journal 2013, 12:263 Page 3 of 14
http://www.malariajournal.com/content/12/1/263(mefloquine, artesunate and its active plasma metabolite,
dihydroartemisinin).
Patients were requested to return for follow-up on
days 7, 14, 21, 28 and 42, or at any time if fever or symp-
toms suggestive of malaria developed. At each visit, a
parasite count was performed (Giemsa-stain), and a de-
tailed questionnaire for general symptoms was recorded.
Blood samples were collected at specified time points
for measurement of mefloquine (at one, two, six, 12, 24,
25, 36, 37, 48, 49 hours, and three and seven days after
the first dose) and artesunate/dihydroartemisinin (at
one, six, 12 and 24 hours after the first dose) concentra-
tions. Malaria blood smears were obtained on enrolment
and thereafter, twice daily until two consecutive slides
were confirmed to be negative, as well as at every
follow-up visit. Thick films were screened for 200 oil-
immersion fields before declaring a slide negative. Asex-
ual parasites and gametocytes were separately counted
against 200 white blood cells (WBCs); if the parasite
density was too numerous to count on the thick film,
the number of parasites per 2,000 red blood cells (RBCs)
on the thin film was counted. Parasite slope half-life for
each patient was calculated from loge (2)/k = 0.693,
where k is the clearance rate constant [15].
Plasmodium falciparum genotyping of the three poly-
morphic genes for surface antigen 1 (msp1), merozoite
surface antigen 2 (msp2), and glutamate-rich protein
(glurp) was performed in paired samples collected prior
to treatment and at the time of parasite re-appearance
to distinguish between re-infection and recrudescence
[16-18]. Blood sample (5 ml) was also collected from
each individual with re-appearance of parasitaemia fordetermination of drug concentrations, in vitro sensitivity
test, and evaluation of potential molecular marker of re-
sistance, P. falciparum multidrug resistance 1 (pfmdr1)
copy number. Clinical efficacy of the three-day course of
artesunate-mefloquine was evaluated in the group of pa-
tients who completed the 42-day follow-up period. The
classification of the therapeutic outcome was according
to the WHO protocol [14]. Plasma concentrations
of artesunate and dihydroartemisinin were measured
using liquid chromatography mass-spectrometry (LC/MS)
according to the method of Thuy and colleagues [19].
Determination of whole blood concentrations of meflo-
quine was performed using high performance liquid chro-
matography with UV-detection (HPLC-UV) according
to the method developed by Karbwang and colleagues
with modification [20].
Assessment of in vitro sensitivity of Plasmodium
falciparum isolates
The in vitro sensitivity test was accomplished in a total
of 76 P. falciparum isolates (60, and 16 isolates collected
pretreatment and at the time of recrudescence, respect-
ively). Plasmodium falciparum 3D7 (chloroquine sensi-
tive) and K1 (chloroquine resistant) were used as control
P. falciparum clones. All were cultured according to the
method of Trager and Jensen with modification [21].
In vitro sensitivity testing was performed in 96-flat-
bottom wells sterile microtiter plate (Costar™, Corning,
Massachusetts, USA) according to the methods of
Rieckmann and colleagues [22]. Evaluation of sensitivity
of P. falciparum isolates to mefloquine and artesunate
was performed based on SYBR Green I assay [23]. The
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were calculated to obtain mean value. The dose re-
sponse curves obtained from in vitro sensitivity assay
were analysed by non-linear regression analysis using
CalcuSyn™ software (Biosoft, Cambridge, UK). Results
were expressed as IC50 value, which is defined as
the concentration of anti-malarial drug that produces
50% inhibition of parasite development as compared to
the control.
The criteria for discrimination between the resistant
and sensitive parasite isolates to mefloquine was as fol-
lows: sensitive (IC50 ≤24 nM), and resistant (IC50 >24 nM)
[24,25]. For artesunate, as there has been no clear cut-off
level for artemisinin resistance, two criteria were applied.
Susceptibility was classified into two levels according to
the criteria of Pradines and colleagues [26], i e, sensitive
(IC50 ≤10.5 nM), and resistant (IC50 >10.5 nM). In
addition, IC50 value of greater than the upper limit of 95%
CI of median defined from sensitive isolate group as previ-
ously applied [27], i e, IC50 >2.8 nM, was considered as de-
clined sensitivity to artesunate [27].
Determination of pfmdr1 copy number by SYBR Green I
quantitative real-time PCR (qRT-PCR)
Investigation of pfmdr1 copy number was performed in
a total of 120 P. falciparum isolates. Sixty-two samples
were obtained from patients with sensitive response dur-
ing the 42-day follow-up period. Twenty-nine paired
samples (58 isolates) were obtained from patients with
recrudescence before treatment and at the time of para-
site reappearance. Genomic DNA was extracted from all
samples using chelex resin modified technique [18].
SYBR Green I qRT-PCR was performed using iCycler™
real-time PCR machine (Bio-Rad, California, USA)
according to the method described by Ferreira and col-
leagues with modification [28]. 3D7 (1 gene copy num-
ber) and Dd2 (4 gene copy number) P. falciparum were
used as positive control clones for pfmdr1 copy number
analysis (provided by Professor Steven A Ward, Liver-
pool School of Tropical Medicine, UK). Distilled water
was used as negative control.
Data analysis
A total of 38 patients with acute uncomplicated
P. falciparum malaria were included in the analysis.
Identification of parasite isolates with intrinsic resistance/
reduced sensitivity to mefloquine and/or artesunate was
analysed in 17 of 29 cases with complete information on
clinico-parasitological response, drug concentrations,
and in vitro sensitivity. Analysis of the contribution of
these three factors in the group with sensitive response
was performed in 21 of 62 cases. Quantitative variables
are summarized as median (95% confidence interval:
95% CI) values, and qualitative variables are presentedas number (%) values. Three criteria were applied for
identification of P. falciparum cases with intrinsic re-
sistance to mefloquine and/or artesunate: (i) PCR-
confirmed recrudescence during a 42-day follow-up
with delayed parasite slope half-life; (ii) adequacy of
mefloquine and/or dihydroartemisinin systemic drug
exposure (AUC); and, (iii) in vitro parasite resistance/
reduced sensitivity to mefloquine and/or artesunate as
defined by the above criteria.
The upper limit of 95% CI of the parasite slope half-
life in the group with sensitive response (2.99 h) was
used as the cut-off for delayed parasite slope half-life.
The lower limits of 95% CI of area under whole blood
mefloquine conentration-time curve from day 0 to day 7
(AUC0-7 days) in patients with sensitive response (8.48
mg.day/ml) was used as a criterion for the adequacy of
mefloquine systemic drug systemic drug exposure. The
lower limit of 95% CI of plasma dihydroartemisinin
concentration-time curve from hour 0 to hour 24
(AUC0-24 h) in patients with sensitive response (462 ng.
h/ml) was used as a criterion for the adequacy of
dihydroartemisinin systemic drug exposure. AUC was
calculated using trapezoidal rule. Association between
mefloquine and dihydroartemisinin systemic exposure
(AUC0-7 days and AUC0-24h) and treatment response was
performed using Fisher's exact test.
Analysis of the correlation between IC50 values of mef-
loquine and artesunate, IC50 values of both drugs and
pfmdr1 copy number, as well as pfmdr1 copy number
and PCT was performed using Spearman’s (rho) correl-
ation test at a statistical significance of α = 0.05 (SPSS
version 15; SPSS, Chicago, Illinois, USA).Results
Pretreatment in vitro sensitivity of Plasmodium falciparum
isolates
The IC50 values of mefloquine in all isolates collected
before treatment ranged from 6.0-118.4 nM, with me-
dian (95% CI) IC50 of 28.0 (21.2-41.0) nM. Based on the
defined criteria, a total of 26 (43.3%) isolates were classi-
fied as mefloquine sensitive (median (95% CI) IC50 =
16.6 (12.9-19.7) nM). The remaining 34 (56.7%) isolates
were classified as mefloquine resistant isolates (median
(95%) of IC50 = 32.0 (35.0-62.2) nM).
The IC50 values of artesunate in all isolates collected
before treatment ranged from 0.3-6.1 nM, with median
(95% CI) IC50 of 1.9 (1.6-2.4) nM. Based on the criteria
defined by Pradines and colleagues [26], all were consid-
ered sensitive to artesunate (median (95% CI) IC50 = 1.9
(1.6-2.4) nM). However, when upper limit of 95% CI of
IC50 in the sensitive was applied as the cut-off criteria,
declining in sensitivity to artesunate was observed in 22
(36.7%) isolates. It was noted however for the relatively
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in all isolates.
A relatively strong positive significant correlation was
observed between the IC50 values of mefloquine and
artesunate (r2 = +0.701; p < 0.001).Pfmdr1 copy number
The analysis of pfmdr1 gene copy number was per-
formed in a total 91 isolates (62 and 29 isolates from pa-
tients with sensitive response and recrudescence,
respectively) recollected before treatment. Most isolates
(40%) carried 1 gene copy, with markedly varied IC50
values. The median (95% CI) IC50 values of mefloquine
in the isolates carrying one, two and three or more than
three pfmdr1 gene copies were 19.3 (14.6-21.5), 37.8
(14.3-61.9), and 60.8 (47.8-70.3) nM, respectively. The
median (95% CI) IC50 values of artesunate in the isolates
carrying one, two and three, or more than three pfmdr1
gene copies, were 1.5 (1.0-1.9), 1.8 (1.4-5.0), and 2.9 (2.0-
3.5) nM, respectively. A significant positive correlation was
found between pfmdr1 copy number and in vitro sensitiv-
ity of P. falciparum isolates to mefloquine (r2 = +0.741,
p < 0.01), and artesunate (r2 = +0.485, p < 0.01) (Figures 2a
and 2b).Identification of resistance of Plasmodium falciparum
isolates to artesunate-mefloquine combination therapy
and pfmdr1 copy number as a candidate molecular
marker of resistance
Identification of resistance of P. falciparum isolates to
artesunate-mefloquine combination therapy was analysed
in 17 out of 29 cases with confirmed recrudescence and
with complete information on clinico-parasitological, drug
concentrations, and in vitro sensitivity (Table 1). Based on
the upper limit of 95% CI of the parasite slope half-life in
patients with sensitive response (2.99 h), all of the patients
with recrudescence had delayed parasite clearance rate.Figure 2 Correlation between pfmdr1 copy number and in vitro sensi
artesunate. (Dashed lines represent the cut-off IC50 values for resistance toRecrudescence occurred between day 14 and 42. There
was no significant difference in IC50 values of both meflo-
quine and artesunate in isolates collected before treatment
from patients with sensitive and recrudescence responses
(median (95% CI): 21.1 (14.6-34.5) vs 49.9 (19.4-69.5) nM
(p = 0.057), and 1.8 (1.4-2.2) vs 2.8 (1.4-3.7) nM (p =
0.093) for mefloquine and artesunate, respectively). Ana-
lysis of paired isolates collected from patients with PCR-
confirmed recrudescence (17 of 29 cases), before and at
the time of parasite re-appearance, revealed no significant
changes in sensitivity to both drugs. Median (95% CI) for
IC50 of mefloquine in paired isolates before and at the
time of recrudescence was 52.6 (19.4-70.2) and 54.9 (19.6-
81.7) nM, respectively (p = 0.10). The corresponding
values for mefloquine IC50 were 2.7 (1.2-3.7) and 3.4 (1.6-
4.6) nM, respectively (p = 0.08).
Based on the previously defined criteria, clinical recru-
descence response with in vitro resistance and/or reduced
intrinsic parasitocidal activity of mefloquine and/or
artesunate without pharmacokinetic or other host-related
factors were confirmed in six cases, two (Nos 13, and 14)
with resistance to mefloquine alone, one (No 16) with re-
duced sensitivity to artesunate alone, and three (Nos 11,
12 and 15) with resistance to mefloquine combined with
reduced sensitivity to artesunate. Clinical recrudescence
response with in vitro resistance and/or reduced intrinsic
paratocidal activity of mefloquine/artesunate, together
with contribution of pharmacokinetic factor of artesunate
and/or mefloquine were confirmed in seven cases: two
(Nos 9 and 10) with resistance to mefloquine alone, and
five (Nos 1, 2, 6, 7 and 8) with resistance to mefloquine
combined with reduced sensitivity to artesunate. Pharma-
cokinetic factor alone contributed to recrudescence in
three cases (Nos 3, 4, and 5), all of which had inadequate
mefloquine AUC0-7 days. Other host-related factors con-
tributed to recrudescence in one case (No. 17) (Table 1).
Pfmdr1 copy number data were available in all of the 17
of 29 PCR-confirmed recrudescence cases with completetivity of Plasmodium falciparum isolates to (a) mefloquine, and (b)
mefloquine/reduced sensitivity to artesunate).
Table 1 Identification of resistance/reduced sensitivity of P. falciparum isolates to artesunate (AS)-mefloquine (MQ) combination therapy was analysed based
on clinico-parasitological response, and in vitro sensitivity and systemic drug exposure during the acute phase of infection and relationship with pfmdr1 copy
number in 17 cases with treatment failure following a three-day combination regimen














Adequate DHA exposure alone (n=5) 1 3.12 Reduced (3.5±0.42) Resistant (58.8±5.1) >1 7.55c 610 (day 21) -Possible AS resistant
-MQ resistant + Inadequate MQ exposure
-Predicted by increased in pfmdr1 copy number
2 3.56 Reduced (4.8±1.07) Resistant (69.5±4.7) >1 8.02c 100 (day 28) -Possible AS resistant
-MQ resistant + Inadequate MQ exposure
-Predicted by increased in pfmdr1 copy number
3 4.23 Sensitive (1.2±0.27) Sensitive (10.6±1.9) 1 6.98c 300 (day 28) -Inadequate MQ exposure
4 3.88 Sensitive (0.7±0.13) Sensitive (6.6±0.4) 1 7.99c 600 (day 33) -Inadequate MQ exposure
5 3.42 Sensitive (0.9±0.10) Sensitive (19.4±0.7) >1 8.07c 720 (day 14) -Inadequate MQ exposure
-Predicted by increased in pfmdr1 copy number
Adequate MQ exposure alone (n=5) 6 3.55 Reduced (3.0±0.06) Resistant (45.3±3.1) >1 320d 324 (day 27) -Possible AS resistant + Inadequate DHA exposure
-MQ resistant
-Predicted by increased in pfmdr1 copy number
7 3.39 Reduced (3.1±0.05) Resistant (70.3±6.3) >1 208d 212 (day 28) -Possible AS resistant + Inadequate DHA exposure
-MQ resistant
-Predicted by increased in pfmdr1 copy number
8 3.56 Reduced (4.2±0.07) Resistant (50.0±4.2) >1 309d 489 (day 21) -Possible AS resistant + Inadequate DHA exposure
-Mefloquine resistant
-Predicted by increased in pfmdr1 copy number
9 3.64 Sensitive (1.8±0.30) Resistant (55.3±4.4) >1 378d 510 (day 28) - Inadequate DHA concentration
-MQ resistant
-Predicted by pfmdr1 copy number
10 3.22 Sensitive (1.4) Resistant (35.0±2.9) >1 489d 402 (day 21) - Inadequate DHA exposure
-MQ resistant
-Predicted by pfmdr1 copy number
Adequate DHA and MQ exposure (n=7) 11 3.97 Reduced (2.9±0.01) Resistant (118.4±6.1) >1 - 1,250 (day 17) -Possible AS resistant
-MQ resistant,

















Table 1 Identification of resistance/reduced sensitivity of P. falciparum isolates to artesunate (AS)-mefloquine (MQ) combination therapy was analysed based
on clinico-parasitological response, and in vitro sensitivity and systemic drug exposure during the acute phase of infection and relationship with pfmdr1 copy
number in 17 cases with treatment failure following a three-day combination regimen (Continued)
12 3.45 Reduced (3.7±0.32) Resistant (95.8±5.4) >1 - 578 (day 14) -Possible AS resistant
-MQ resistant
-Predicted by increased in Pfmdr1 copy number
13 3.33 Sensitive (1.7±0.16) Resistant (28.8±5.5) >1 - 102 (day 35) -MQ resistant
-Predicted by pfmdr1 copy number
14 3.56 Sensitive (1.9±0.10) Resistant (60.8±7.1) >1 - 620 (day 14) -MQ resistant
-Predicted by pfmdr1 copy number
15 3.65 Reduced (3.7±0.21) Resistant (25.5±0.2) 1 - 610 (day 24) -Possible AS resistant
-MQ resistant
16 3.56 Reduced (5.2±0.85) Sensitive (16.6±0.8 1 - 107 (day 35) -Possible AS resistant
17 3.44 Sensitive (0.9±0.08) Sensitive (16.5±2.4) 1 - 67 (day 42) -Other host-related factors
a Delayed parasite slope half-life if >2.99 h.
b Mean + SD of three experiments, triplicate each.
c MQ AUC0-7d which was lower than the lower limit of 95% CI (8.48 mg.day/ml).
d DHA AUC0-24h which was lower than the lower limit of 95% CI (8.48 ng.h/ml).
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drug exposure during acute phase and in vitro parasite
sensitivity. Twelve of 17 (70.1%) isolates in the group with
recrudescence response respectively carried >1 pfmdr1
copy number. Increase in pfmdr1 copy number was asso-
ciated with reduced/resistance to mefloquine alone, and
artesunate together with mefloquine in 11 cases (four
cases, respectively) (Table 1).
Analysis of contribution of in vitro parasite sensitivity and
systemic drug exposure and relationship with pfmdr1
copy number in patients with sensitive response
Analysis of the contribution of in vitro parasite sensitiv-
ity and systemic drug exposure including relationship
with pfmdr1 copy number in the group with sensitive re-
sponse was evaluable in 21 of 69 cases (Table 2). Clinical
sensitive response with in vitro resistance and/or re-
duced intrinsic parasitocidal activity of mefloquine and/
or artesunate without pharmacokinetic factors was con-
firmed in four cases: one (No 35) with resistance to mef-
loquine alone, and three (Nos 31, 32 and 33) with
resistance to mefloquine combined with reduced sensi-
tivity to artesunate. Clinical sensitive response with
in vitro resistance and/or reduced intrinsic parasitocidal
activity of mefloquine/artesunate, together with contri-
bution of pharmacokinetic factor of mefloquine and/or
artesunate were confirmed in five cases: three (Nos 20,
25 and 27) with resistance to mefloquine alone, and two
(Nos 18 and 22) with resistance to mefloquine combined
with reduced sensitivity to artesunate. Inadequacy of sys-
temic drug exposure was found in 13 cases: four with in-
adequate mefloquine exposure alone (Nos 18, 19, 20,
and 21), nine with inadequate dihydroartemisinin expos-
ure alone (Nos 22, 23, 24, 25, 26, 27, 28, 29 and 30), and
two with inadequate exposure of both mefloquine and
dihydroartemisinin (Nos 37 and 38).
Pfmdr1 copy number data were available in all of the 21
cases with complete information on clinico-parasitological
response, drug concentrations and in vitro parasite sensi-
tivity. Fifteen of 21 (71.4%) carried only one pfmdr1 copy
number (Table 2).
Association between treatment response and systemic
drug exposure
No significant association between mefloquine and
dihydroartemisinin exposure (AUC0-7 days and AUC0-24h)
and treatment response was found (p = 0.137 and 0.583,
respectively).
Discussion
Accumulating evidence suggests a decline in the effi-
cacy and some degree of resistance of P. falciparum in
the Greater Maekong Subregion (GMS) to artemisinins.
Early evidence came from western Cambodia and theThai-Cambodian border in patients following treatment
with either artesunate monotherapy or artesunate-
mefloquine [2,3,9,10]. Although results of the contain-
ment project in seven provinces of Thailand bordering
Cambodia (Buriram, Chantaburi, Sakaew, Srisaket,
Surin, and Trat) during 2009–2011, in a total of 1,709
P. falciparum-positive cases, suggest that the thera-
peutic efficacy of artesunate-mefloquine remains at an
acceptable level with cure rate of greater than 90%, con-
tinuous monitoring of P. falciparum resistance in both
border areas is critical [29]. With regard to the Thai-
Myanmar border, until recently [11,12], there has been
no clear evidence of a significant reduction in artemisi-
nin efficacy at either clinical or in vitro sensitivity level.
A longitudinal investigation in a total of 3,202 patients
during 2001–2010 from malaria clinics, Shoklo Malaria
Research Unit, Tak Province, unveiled that genetically
determined artemisinin resistance in P. falciparum may
have emerged along the Thai-Myanmar border at least
eight years ago and has since markedly increased [12].
The clinical efficacy of artesunate-mefloquine combin-
ation therapy is beginning to decline in the Thai-
Myanmar border and resistance is not only confined to
western Cambodia and areas along the Thai-Cambodian
border. Due to the limitation of the study design how-
ever, it was not possible to attribute treatment failures
in these studies to resistance or host-related factors (e g,
pharmacokinetics). Furthermore, if resistance actually
occurred, it was unclear whether this was due to intrin-
sic parasite resistance to artesunate alone, mefloquine
alone, or both, because of the pre-existing background
of mefloquine resistance in these areas. In order to ex-
clude the contribution of host and confounding factors
from the partner drug mefloquine, a series of investiga-
tion with artesunate monotherapy (2–6 mg/kg body
weight/day for seven days) was performed during 2006–
2008 using stringent criteria for defining artemisinin re-
sistance with integrated in vivo-in vitro approach [4-8].
The present study was designed to identify the treat-
ment failure cases due to intrinsic parasite factor to each
component of the three-day regimen. Resistance or de-
cline in parasite susceptibility was confirmed based on
integrated information on clinicopathological assessment
together with in vitro sensitivity (intrinsic parasite resist-
ance) and systemic drug exposure (pharmacokinetic fac-
tor) in 17 out of 29 patients with recrudescence (LPF)
following treatment with a three-day combination regi-
men of artesunate-mefloquine [11]. All had significant
delay in parasite clearance rate (slope half-life) compared
with the sensitive cases. Despite the fact that the delay
in parasite clearance is influenced by host-related fac-
tors, it is proposed as a sensitive marker of reduced sus-
ceptibility of artemisinin component of the ACT than
recrudescence rate [30]. The main effect of artemisinins
Table 2 Analysis of contribution of in vitro parasite sensitivity and systemic drug exposure during acute phase of infection and relationship with pfmdr1 copy











Conclusion on parasite sensitivity and
adequacy of systemic drung exposureAS MQ
Adequate DHA exposure alone (n= 4) 18 2.90 Reduced (2.4±1.0) Resistant (34.5±3.2) >1 8.40c -Possible AS resistant
-MQ resistant + Inadequate MQ exposure
19 2.97 Sensitive (1.1±0.15) Sensitive (8.0±1.4) 1 6.78c -AS sensitive
-MQ sensitive + Inadequate MQ exposure
-Predicted by pfmdr1 copy number
20 3.01 Sensitive (2.0±0.25) Resistant (31.3±1.6) 1 7.77c - AS sensitive
- MQ resistant + Inadequate MQ exposure
-Predicted by pfmdr1 copy number
21 2.78 Sensitive (1.8±0.13) Sensitive (17.5±3.0) 1 7.09c -AS sensitive
- MQ sensitive + Inadequate MQ exposure
-Predicted by pfmdr1 copy number
Adequate MQ exposure alone (n=9) 22 3.11 Reduced (3.2±0.15) Resistant (90.0±16.5) 1 402d -Possible AS resistant + Inadequate DHA exposure
-MQ resistant
-Predicted by pfmdr1 copy number
23 3.23 Sensitive (0.4±0.04) Sensitive (14.6±2.2) 1 389d -AS sensitive + Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number
24 2.78 Sensitive (0.3±0.10) Sensitive (13.7±2.4) 1 390d -AS sensitive+ Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number
25 3.01 Sensitive (1.8±0.31) Resistant (47.5±1.7) >1 391d -AS sensitive + Inadequate DHA exposure
-MQ resistant
26 2.89 Sensitive (1.6±0.30) Sensitive (20.9±0.5) 1 398d -AS sensitive+ Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number entration
27 2.77 Sensitive (1.6±0.24) Resistant (27.1±1.0) 1 450d -Possible AS resistant + Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number
28 3.01 Sensitive (1.9±0.35) Sensitive (18.5±2.4) 1 409d -AS sensitive + Inadequate DHA exposure
-MQ sensitive

















Table 2 Analysis of contribution of in vitro parasite sensitivity and systemic drug exposure during acute phase of infection and relationship with pfmdr1 copy
number in patients with sensitive response following treatment with a three-day artesunate (AS)-mefloquine (MQ) combination regimen (Continued)
29 2.89 Sensitive (1.0±0.03) Sensitive (8.1±0.1) 1 379d -AS sensitive + Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number
30 3.01 Sensitive (2.2±0.16) Sensitive (19.1±1.0) 1 423d -AS sensitive + Inadequate DHA exposure
-MQ sensitive
-Predicted by pfmdr1 copy number
Adequate DHA and MQ exposure (n=6) 31 2.67 Reduced (3.4±0.44) Resistant (100.7±16.8) >1 - -Possible AS resistant
-MQ resistant
32 2.89 Reduced (3.8±0.62) Resistant (62.2±4.6) >1 - -Possible AS resistant
-MQ resistant
33 3.00 Reduced (3.3±0.37) Resistant (60.0±4.2) >1 - -Possible AS resistant
-MQ resistant
34 3.00 Sensitive (1.4±0.31) Sensitive (6.8±0.5) 1 - -AS sensitive
-MQ sensitive
-Predicted by pfmdr1 copy number
35 2.09 Sensitive (0.9±0.13) Resistant (25.1±0.2) 1 - -AS sensitive
-MQ resistant
-Predicted by pfmdr1 copy number
36 2.89 Sensitive (1.6±0.19) Sensitive (21.2±0.3) 1 - -AS sensitive
-MQ sensitive
-Predicted by pfmdr1 copy number
Inadequate DHA and MQ exposure (n=2) 37 2.90 Sensitive (1.5±0.23) Sensitive (14.3±2.7) >1 5.34c -AS sensitive
234d -MQ sensitive
38 3.01 Sensitive (1.9±0.28) Sensitive (22.1±0.4) 1 7.09c -AS sensitive
209d -MQ sensitive
-Predicted by pfmdr1 copy number
a Delayed parasite slope half-life if > 2.99 h.
b Mean ± SD of 3 experiments, triplicate each.
c MQ AUC0-7d which was lower than the lower limit of 95% CI (8.48 μg.day/ml).
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in parasite clearance and thus, the slope half-life [15].
Resistance of the P. falciparum isolates to mefloquine
or aretsunate was defined according to in vitro sensitiv-
ity criteria. Existing data on the relationship between
in vitro sensitivity and artemisinin are controversial. Al-
though lack of significant correlation between in vitro
sensitivity of artemisinins and clinical response was
found in some studies [4,31], good correlation was ob-
served in most studies [2,3,9,26,32,33]. Adequacy of
mefloquine and dihydroartemisinin systemic drug ex-
posure was defined based on the lower limits of 95% CI
of the median AUC0-7 days and AUC0-24h, respectively, in
the sensitive group. Based on this defined criteria, re-
sults suggest that low level of a decline in sensitivity of
P. falciparum to artesunate (in terms of a small increase
in IC50 of artesunate and number of identified cases
with reduced sensitivity to artesunate) exists in this area
on a background of pre-existing mefloquine resistance,
and both parasite in conjunction with host-related fac-
tors significantly contributed to high failure rate in this
group of patients. There was only one (out of 17) con-
firmed case with reduced sensitivity to artesunate alone,
while there were three cases with reduced sensitivity/re-
sistance to both artesunate and mefloquine. Pharmaco-
kinetic factor contributed to about 58.8% (10 of 17
cases) of the total recrudescence cases. Inadequacy of
mefloquine and dihydrortemisinin systemic drug expos-
ure was observed in five and five cases, respectively.
However, there was no significant difference in the
systemic exposure of both mefloquine and dihydro-
artemisinin (AUC0-7 days and AUC0-24h) in patients with
treatment failure compared with those with sensitive
response.
Host-related factor contributing to treatment failure in
one case could not be definitely defined. It is noted that
the in vitro sensitivity of the only one isolate with identi-
fied resistance/reduced sensitivity to artesunate alone
(No 16) was markedly low compared with others (IC50
5.2 nM). Furthermore, in one (No 11) of the three cases
with in vitro resistance/reduced sensitivity to both mef-
loquine and artesunate, mefloquine concentration of as
high as 1,250 ng/ml was detected on the day of recru-
descence (day 17). It is of note that this high level was
still inadequate to completely eliminate residual parasites
on background of resistance/reduced sensitivity to both
mefloquine and artesunate. In the other two cases with
contribution of mefloquine pharmacokinetic factor (Nos
1 and 2), variable whole blood mefloquine concentration
on the days of recrudescence of 610 and 100 ng/ml was
observed. The relatively low drug concentrations in
some of the recrudescence cases could be due to variabil-
ity in pharmacokinetics of mefloquine and artesunate/
dihydroartemisinin, and these concentrations were nolonger adequate once the level of resistance to either mef-
loquine or artesunate was aggravated. Systemic exposure
of both drugs during the acute phase infection was used
as a criterion to define adequacy of drug levels. Whole
blood mefloquine concentration on day 1 of treatment has
been reported to be an important determinant of success-
ful treatment [34], but there has been no defined threshold
levels of artesunate/dihydroartemisinin for treatment of
falciparum malaria. Sensitivity of P. falciparum isolates in
this area to mefloquine was still at the resistance level
(43.3% of the isolates with recrudescence) after a certain
period of improvement [27]. Mefloquine was used as
monotherapeutic treatment of acute uncomplicated falcip-
arum in this area long before the introduction of the com-
bination regimen and thus mefloquine resistance had
already reached a level too extreme to protect the develop-
ment and spread of artesunate resistance. The sensitivity
of P. falciparum to artemisinins would be compromised
by intensifying resistance to mefloquine. Decline of in vitro
sensitivity of parasite in this, as well as other areas to
artesunate has been demonstrated [4,7,35] and it is noted
for a ten-fold decrease in in vitro artemisinin sensitivity
observed over a 10-year period in north-western Thailand
[36]. In a previous study, decreased in vitro susceptibility
to dihydroartemisinin (IC50 21.2 nM) and artesunate
(16.3 nM) was reported in a patient returning from south
of Laos and north of Thailand [26]. In view of the short
half-life of oral artesunate on the other hand, it is expected
that the drug exerts little drug pressure, provided the
treatment generally results in parasitological cure. Com-
pared with western Cambodia and areas along the Thai-
Cambodian border, intensity of malaria transmission is
relatively low in the north-western border areas of
Thailand. This would lead to lower selective drug pressure
and drug resistance. Although artemisinin resistance starts
to gradually emerge [37,38], relatively good parasitologic
responses to artemisinins are observed in this border area
even after almost 20 years of intensive use [31].
Analysis of the contribution of in vitro parasite sensitiv-
ity and drug concentrations and relationship with pfmdr1
copy number in the group with sensitive response was
performed in 21 of 69 cases. Results indicate contribution
of both parasite and pharmacokinetic factors in treatment
response, but with different magnitude. Pharmacokinetic
factor contributed to 71.4% (15 of 21 cases) of variation in
mefloquine and/or dihydroartemisinin concentrations in
this group of patients, of which 35.3% (six of 17 cases)
were due to variable mefloquine pharmacokinetics (alone
or together with dihydroartemisinin) and 64.7% (11 of 17
cases) were due to variable artesunate/dihydroartemisinin
pharmacokinetics (alone or together with mefloquine). In
vitro resistance/reduced sensitivity to mefloquine and
aresunate was found in 36.7% (nine of 17 cases) and 43.3%
(12 of 17 cases) of all cases, respecrtively. In the group
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contributed to 58.8% (ten of 17 cases) of variation in mel-
foquine and/or dihydroartemisinin concentrations; 50%
(five of ten cases) were due to variable mefloquine phar-
macokinetics (alone or together with dihydroartemisinin)
and 50% (five of ten cases) were due to variable
artesunate/dihydroartemisinin pharmacokinetics (alone or
together with mefloquine). Resistance/reduced sensitivity
to mefloquine and aresunate was found in 23.8% (five of
21 cases) and 42.9% (nine of 21 cases) of all cases, respect-
ively. Altogether, these findings may suggest that the
influence of pharmacokinetic variability of mefloquine in-
fluences more on treatment response than of artesunate/
dihydroartemisinin on background of mefloquine resist-
ance together with decreasing susceptibility of parasite to
artesunate. Although statistical significance could not be
achieved due to a marked variability, the IC50 of both
artesunate (medians of 49.9 vs 21.1 nM) and mefloquine
(medians of 2.8 vs 1.8 nM) tended to be higher in isolates
obtained from patients with recrudescence response. In
the two cases with sensitive response (Nos 18 and 20),
sensitivity of the parasite to both artesunate and meflo-
quine is relatively high and even with low systemic expos-
ure of mefloquine, were still adequate to completely
eliminate all the parasites. In the other three cases (Nos
31, 32 and 33) with in vitro resistance/reduced sensitivity
to mefloquine and artesunate, radical cure could be
obtained as far as adequate systemic exposure of both
mefloquine and dihydroartemisinin were achieved.
A consensus for the molecular and cellular mecha-
nisms of artemisinin resistance has not emerged. Des-
pite continuous efforts to uncover definite molecular
markers for resistance to artemisinins in P. falciparum,
no valid marker has been identified and confirmed,
which precludes efficient monitoring of emerging and
spreading resistance. Results from various molecular
studies varied, probably reflecting a multigenetic nature
of artemisinin resistance. Among these, polymorphisms
of PfMDR1 (an ATP-binding cassette (ABC) transporter
residing on the digestive vacuolar membrane of the
parasite, where it transports solutes, including anti-
malarial drugs into the digestive vacuole) encoded by
the pfmdr1 gene have received the most attention. Sev-
eral mutations (N86Y, Y184F, S1034C, N1042D and
D1246Y) and copy number variation that occurred in
pfmdr1 from field isolates collected from several en-
demic areas are associated with altered sensitivity to
artemisinins and their combination partner mefloquine
[39-42]. Amplification of PfMDR1 copy number has
been proposed as a key determinant for both in vivo
and in vitro resistance to both artemisinins and me-
floquine in Cambodia and areas along the Thai-
Cambodian and Thai-Myanmar borders [26,35,43-47].
Nevertheless, some clinical trials could not confirm thelink between PfMDR1 polymorphism/copy variation
and artemisinin resistance [4-8]. There appeared to be
no association between the mutation or amplification of
pfatp6, the sarco/endoplasmic reticulum Ca2+-ATPase,
in P. falciparum isolates in Thailand [38]. In this study,
increased copy number of pfmdr1 was shown to be as-
sociated with treatment failure and a decline in in vitro
susceptibility of P. falciparum isolates in this area fol-
lowing artesunate-mefloquine combination, with ap-
proximately 40% of the isolates carrying pfmdr1 copy
number between two and six copies. Pfmdr1 copy num-
ber correlated well with clinical treatment response in
both groups of patients with sensitive and recrudes-
cence response. Approximately 70.1% (12 of 17 cases)
and 71.4% (15 of 21 cases) in the groups with sensitive
and recrudescence response carried gene copy number
>1 (two to six) and one, respectively. Resistance to ACT
may evolve even when the two drugs within the
combination are taken simultaneously and amplifica-
tion of the pfmdr1 gene may partly contribute to this
phenotype.
Conclusions
Despite the evidence of a low level of a decline in sensi-
tivity of P. falciparum isolates to artemisinins in areas
along the Thai-Myanmar border, ACT would be expected
to remain the key anti-malarial drug for treatment of
multidrug resistance P. falciparum. Continued monitor-
ing and active surveillance of clinical efficacy of ACT
including identification of true artemisinin resistant
parasite is required for appropriate implementation of
malaria control policy in this area.
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